Panel Discussion – Barriers to Development of CD73/CD39 Mono and Combo Therapies and Potential Solutions

Time: 11:00 am
day: Day Two


  • Compare and contrast single vs dual inhibition of adenosine enzymes
  • Explore current challenges with identifying and validating predictive biomarkers of response
  • Suggest methods and technologies worth pursuing to better select patients for trials